Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006359 · ClinicalTrials.gov registry record · Phase 2
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT00006359: Completed Phase 2 study of Prostate Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00006359 is a Phase 2 study of Prostate Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 63 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006359, a Phase 2 study of Prostate Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving these drugs together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well androgen suppression with either leuprolide or goserelin and either flutamide or bicalutamide together with radiation therapy works in treating patients with prostate cancer.
Conditions Studied
Interventions
- DRUG LHRH agonist
- RADIATION radiation therapy
- DRUG antiandrogen
- RADIATION Brachytherapy boost
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. - Syracuse
- SUNY Upstate Medical University Hospital - Syracuse
- Veterans Affairs Medical Center - Syracuse - Syracuse
- Community General Hospital of Greater Syracuse - Syracuse
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
- Hudner Oncology Center at Saint Anne's Hospital - Fall River
- UMASS Memorial Cancer Center - University Campus - Worcester
Missouri
- Ellis Fischel Cancer Center at University of Missouri - Columbia - Columbia
- CCOP - Kansas City - Kansas City
- Missouri Baptist Cancer Center - St Louis
- Arch Medical Services, Incoroporated at Center for Cancer Care Research - St Louis
Delaware
- Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
- St. Francis Hospital - Wilmington
Florida
- Florida Hospital Cancer Institute at Florida Hospital Orlando - Orlando
Maryland
- Union Hospital Cancer Center at Union Hospital - Elkton MD
Nevada
- Washoe Cancer Services at Washoe Medical Center - Reno - Reno
New Jersey
- Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2000-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT00006359 record still lists
NCT00006359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which LHRH agonist is the first listed.
NCT00006359 names 20 study sites across 8 states, led by New York, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT00006359 about?
NCT00006359 is a clinical study titled "Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving these drugs together with radiation therapy...
What is the current status of trial NCT00006359?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2000-09. Estimated completion is 2012-03.
What conditions does trial NCT00006359 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00006359?
The interventions under investigation include: LHRH agonist (DRUG), radiation therapy (RADIATION), antiandrogen (DRUG), Brachytherapy boost (RADIATION).
Who is sponsoring clinical trial NCT00006359?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006359 being conducted?
This trial has 20 study locations across Delaware, Florida, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006359's enrollment target sits among peer trials
63 415th of 735 higher than 320 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia